Gamma-glutamyl transferase levels are associated with the occurrence of post-stroke cognitive impairment: a multicenter cohort study

Table 3 Association between GGT levels and PSCI incidence at 3 months follow-up

Outcomes	GGT	No.	Events, N (%)	Unadjusted	Model 1	Model 2	Model 3
Outcomes	GGT	No.	Events, N (%)	OR (95%CI) P value	OR (95%CI) P value	OR (95%CI) P value	OR (95%CI) P value
PSCI	Q1	207	43.13	1	1	1	1
	Q2	162	35.60	0.73(0.56-0.95) 0.02	0.86(0.65-1.13) 0.27	0.83(0.63-1.10) 0.20	0.82(0.61-1.10) 0.18
	Q3	156	30.12	0.57(0.44-0.74) < 0.001	0.73(0.56-0.97) 0.03	0.71(0.53-0.94) 0.02	0.69(0.51-0.93) 0.02
	Q4	146	28.97	0.54(0.41-0.70) < 0.001	0.80(0.60-1.07) 0.14	0.76(0.57-1.02) 0.07	0.69(0.50-0.96) 0.03

Data are presented as OR (95% CI). Set OR of quartile 1 as the reference. Model 1: adjusted by age, sex, educational level; Model 2: adjusted by model 1 plus BMI, medical history, current smoking, current drinking, and medication use (diabetes mellitus, hypoglycemic therapy, antidepressant therapy, sedative-hypnotic therapy); Model 3: adjusted by model 2 plus TOAST type, laboratory tests (LDL, HDL, TC, TG, ALT, AST, eGFR, UA, and Albumin levels); PSCI post-stroke cognitive impairment, GGT gamma-glutamyl transferase, BMI body mass index, TOAST the Trial of ORG 10172 in Acute Stroke Treatment, LDL low-density lipoprotein, HDL high-density lipoprotein; TG triglycerides, TC total cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, eGFR effective glomerular filtration rate, UA uric acid, OR odds ratio, CI confidence interval

ISSN: 1471-2377